From our friends at AEI, a wonderful capture of the difference between the Obama/Biden jobs "recovery…
CFIF on Twitter CFIF on YouTube
Image(s) of the Day: The Obama/Biden Jobs "Recovery" Versus Trump's

From our friends at AEI, a wonderful capture of the difference between the Obama/Biden jobs "recovery," which was the worst in recorded U.S. history (as the graph shows, they promised that unemployment wouldn't surpass 8% under their wasteful spending "stimulus," but instead it exceeded 8% for a record uninterrupted stretch), versus the sharp recovery under President Trump:

[caption id="" align="alignleft" width="557"] The Obama/Biden Jobs "Recovery"[/caption]

 

 

 

[caption id="" align="alignleft" width="557"] The Trump Actual Jobs Recovery[/caption]…[more]

September 25, 2020 • 10:07 AM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's CourtroomLegal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts.
Home Press Room CFIF Opposes State Attorneys General “March-In” Demand on Remdesivir
CFIF Opposes State Attorneys General “March-In” Demand on Remdesivir Print
Thursday, August 06 2020

ALEXANDRIA, VA – This week, a group of state attorneys general issued a joint letter to the United States Department of Health and Human Services (HHS), National Institutes of Health (NIH) and Food and Drug Administration (FDA) demanding that the federal government employ so-called “march-in” rights under the Bayh-Dole Act of 1980 to disregard Gilead Sciences, Inc.’s patent rights on its antiviral drug Remdesivir, or allow their states to do so.  The Center for Individual Freedom (CFIF) strongly opposes their demand.  

“If you seek to bring pharmaceutical innovation to a grinding halt, and deprive Americans of lifesaving drugs, the best way to do it is to flagrantly disregard patent protections for pharmaceutical innovators,” said Timothy Lee, CFIF’s Senior Vice President of Legal and Public Affairs.  “Unfortunately, that’s precisely the path that a misguided group of state attorneys general have decided to pursue.  Violating innovators’ patent rights won’t make drugs cheaper, it will only deprive consumers of potentially beneficial drugs entirely.  America currently produces two-thirds of all new drugs worldwide, and that’s because our nation honors and protects patent rights, it doesn’t violate them,” Lee added.    

“It’s particularly galling that the attorneys’ general seek to leverage the Bayh-Dole Act of 1980 to facilitate their scheme, and as we celebrate the law’s 40th anniversary to boot,” Lee continued.  “The Bayh-Dole Act was passed in order to extend patent rights to universities and nonprofit research entities whose research was assisted by federal funds, not weaken them.”  

Prior to Bayh-Dole, very few innovations partially funded by federal dollars were ever commercially pursued – only 390 in the year prior to its passage.  Forty years later, however, that number approaches 7,500, with over 420,000 inventions and 13,000 new startup enterprises formed.  

In the case of Remdesivir, Gilead Sciences has invested billions of dollars in research, development, testing and now manufacturing of the antiviral drug, including over $1 billion this year alone to expand manufacturing capacity both domestically and abroad.  Moreover, Remdesivir’s patents are held by Gilead Sciences, not other researchers or entities that received federal funding at various points in the drug’s creation and production.  Accordingly, Bayh-Dole doesn’t offer the legal means by which the attorneys general seek to achieve their counterproductive ends.  

Fortunately, HHS officials have expressed strict opposition to this scheme.  “CFIF strongly encourages the Trump Administration, HHS, NIH and FDA to maintain their rejection, and instead strengthen rather than limit patent rights for America’s world-leading pharmaceutical innovators, particularly in this time of critical societal need,” Lee concluded.  

CFIF is a constitutional and free market advocacy organization with over 300,000 supporters and activists nationwide.  

###

Related Articles :
Question of the Week   
Who was first President to nominate a woman to the U.S. Supreme Court?
More Questions
Quote of the Day   
 
"Chairman of the Senate Judiciary Committee Lindsey Graham hinted more than a week ago that more bombshell information regarding the FBI's handling of its probe into President Donald Trump's campaign and Russia was about to be public. He was right because it was Graham's committee that discovered the information.In a bombshell letter released a letter Thursday night by Graham's committee from Justice…[more]
 
 
—Sara A. Carter, National and International Award Winning Investigative Reporter
— Sara A. Carter, National and International Award Winning Investigative Reporter
 
Liberty Poll   

From which political party are you seeing the most concentrated voter registration efforts in your area?